Cryoport Systems Unveils Cutting-Edge Global Supply Chain Center in Paris, Elevating Life Sciences Logistics

Cryoport Systems, a global leader in temperature-controlled supply chain solutions for the life sciences industry, has proudly announced the grand opening of its latest Global Supply Chain Center (GSCC) in the bustling metropolis of Paris, France. This strategic expansion marks a significant milestone in the company's commitment to bolstering its global infrastructure and enhancing its support for the rapidly evolving cell and gene therapy market across Europe, the Middle East, and Africa (EMEA) and beyond.

The state-of-the-art facility is strategically located just minutes from Paris Charles de Gaulle Airport (CDG), a critical transportation hub.

This prime location is a game-changer, promising optimized logistics, reduced transit times, and unparalleled efficiency for the highly sensitive and time-critical biopharmaceutical shipments that are the hallmark of advanced therapies. By positioning this new center at such a pivotal crossroads, Cryoport Systems is not only expanding its footprint but also fortifying its entire global network.

Designed with the future of personalized medicine in mind, the new Paris GSCC boasts a substantially larger footprint and significantly increased capacity compared to its predecessor.

It is meticulously engineered to manage the intricate needs of advanced therapy products, offering comprehensive solutions for Cryoport Express® Shippers, a cornerstone of Cryoport's cold chain management expertise. Furthermore, the center will serve as a hub for Cryoport Consulting Solutions, providing expert guidance and tailored strategies to clients navigating the complexities of the biopharmaceutical supply chain.

Dr.

Mark Sawicki, President and CEO of Cryoport Systems, emphasized the profound impact of this expansion, stating, “The inauguration of our new Global Supply Chain Center in Paris underscores Cryoport Systems’ unwavering dedication to meeting the escalating demands of our clients worldwide, particularly within the dynamic cell and gene therapy sector.

This facility represents a critical enhancement to our global logistics capabilities, allowing us to deliver even more seamless, reliable, and efficient services crucial for these life-saving therapies.”

The investment in this cutting-edge facility aligns perfectly with Cryoport Systems’ broader vision of advancing global health.

It is not merely an expansion of physical space but an enhancement of operational excellence, improving the responsiveness and resilience of the temperature-controlled supply chain. This move is also a testament to the company's focus on sustainability, as enhanced logistical efficiency often translates into a reduced environmental footprint through optimized routes and reduced energy consumption.

As the cell and gene therapy market continues its exponential growth, the need for robust, reliable, and compliant cold chain solutions becomes ever more critical.

Cryoport Systems' new Paris GSCC is poised to play a pivotal role in addressing this demand, ensuring that groundbreaking therapies reach patients safely and effectively. This facility is more than just a logistics center; it is a symbol of innovation, a commitment to quality, and a beacon of hope for patients awaiting these revolutionary treatments.